Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126307081 | 12630708 | 1 | I | 20160729 | 20160808 | 20160808 | PER | US-PFIZER INC-2016368739 | PFIZER | 0.00 | F | Y | 0.00000 | 20160808 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126307081 | 12630708 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 25 MG, 2X/DAY | 20699 | 25 | MG | PROLONGED-RELEASE CAPSULE | BID | ||||||
| 126307081 | 12630708 | 2 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | 50 MG, 3X/DAY | 20699 | 50 | MG | PROLONGED-RELEASE CAPSULE | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126307081 | 12630708 | 1 | Depression |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126307081 | 12630708 | Anxiety | |
| 126307081 | 12630708 | Decreased activity | |
| 126307081 | 12630708 | Decreased appetite | |
| 126307081 | 12630708 | Tremor |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126307081 | 12630708 | 1 | 201606 | 0 |